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In this work, we present a bottom-up approach for the synthesis of lactose-functionalized
glycomacromolecules and glycofunctionalized liposomes and apply these compounds to investigate
their eﬀects of multivalent presentation on binding to galectin-3. Step-wise assembly of tailor-made
building blocks on solid supports was used to synthesize a series of oligo(amidoamine) scaﬀolds that
were further conjugated to lactose via copper catalyzed 1,3-dipolar cycloaddition. Binding studies with
galectin-3 revealed aﬃnities in the micromolar range that increased with increasing carbohydrate
valency, and decreased with increasing size and linker ﬂexibility. To further explore their multivalency,
selected glycomacromolecules were conjugated to lipids and used in liposomal formulations. Binding
studies show a further increase in binding in nanomolar ranges in dependence of both ligand structure
and liposomal presentation, demonstrating the power of combining the two approaches.Introduction
Carbohydrate–protein interactions play crucial roles in various
biological binding processes such as cell–cell communication
and tumor biology.1 An important family of carbohydrate-
recognizing proteins are the galectins (Gal).2,3 Galectins have
been shown to be involved in apoptosis, angiogenesis, cell–cell
communication, immunemaintenance and cell proliferation.4–7
There are currently een members of the galectin family,
which are further subclassied into three groups: prototype (e.g.
Gal-1), tandem-repeat (e.g. Gal-9) and chimeric (Gal-3).8 Galec-
tins bind to b-galactoside terminating saccharides, most
notably LacNAc (Galb1-4GlcNAc), through their conserved
carbohydrate recognition domain (CRD).8 The galectin CRD is
composed of ve binding sites A–E, where C binds the galactose
moiety and D the carbohydrate attached at the reducing end of
the galactose residue.2,9 Gal-3, the only chimeric type galectin, is
one of the best studied members4,5,10,11 and is an importantlar Chemistry, Heinrich-Heine-University
Du¨sseldorf, Germany. E-mail: laura.
; Tel: +49-211-81-10360
Biotechnology, Helmholtz-Institute for
versity, Pauwelsstraße 20, 52074 Aachen,
erfaces, Mu¨hlenberg 1, 14424 Potsdam,
e, North Carolina 28035, USA
ESI) available: 1H-NMR, HR-ESI, LCMS,
97target to develop synthetic ligands to better understand the role
of Gal-3 in normal and diseased process as well as for the
development of new diagnostics and therapeutics.5
The natural multivalent ligands for Gal-3 are mostly glycans
and glycoproteins such as laminin or bronectin with O- and N-
linked glycans that oen terminate in repeating LacNAc
units.12–15 Given the challenging synthesis of such poly-
saccharides or glycoproteins, the synthesis of more simplied
multivalent glycomimetics as ligands of galectins is gaining
attention.16–18 Multivalent glycomimetics oen consist of
a synthetic scaﬀold such as a peptide or polymer presenting
multiple copies of a polysaccharide fragment.18–20 For example,
successful implementation of glycomimetics targeting Gal-3
was shown by Becer and co-workers who synthesized a series
of glycopolypeptides varying in the spacing and density of
carbohydrate ligands.21 In another example, Kamerling and co-
workers used solid phase synthesis to generate glycopeptide
libraries to study Gal-3.22,23 Cloninger and co-workers18,24 used
dendritic scaﬀolds for the multivalent presentation of carbo-
hydrates and demonstrated their ability to induce Gal-3 aggre-
gation and inhibit cancer cellular aggregation, while Percec and
co-workers used glycodendrimers and dendrimersomes to
present lactose to diﬀerent galectins including Gal-1,25,26 Gal-3
and -4,27,28 and Gal-8 26,28,29 to explore their properties. Gabius
and Roy evaluated diﬀerent kinds of glycomimetics from di- to
tetra-conjugated lactose-functionalized glycoclusters to non-
acontavalent lactoside glycodendrimers and demonstrated
their potential in solid phase as well as in cell assays.30–33 Bon-





























































































View Article Onlinemultivalent presentation of carbohydrates for galectin
binding.34 Additionally, in the group of Elling, the enzymatic
build-up of glycans and their subsequent conjugation to bovine
serum albumin (BSA) to form so-called neo-glycoproteins was
used to demonstrate the eﬀect of multivalency in Gal-3
recognition.35,36
Another strategy for a multivalent presentation, which is, to
the best of our knowledge unexplored for Gal-3, is the use of
surface functionalized liposomes.37–42 The synthesis of carbo-
hydrate–lipid conjugates and their incorporation into lipo-
somes via self-assembly allows for the build-up of multivalent,
supramolecular structures, which can be used as ligands, drug-
or antigen-delivery systems.43–47 The use of natural membrane
compounds like cholesterol and phosphatidylcholines (e.g.
DSPC) for the formulation of liposomes can furthermore ensure
a higher biocompatibility for biological applications. Thus, the
presentation of glycomimetics on the surface of such supra-
molecular systems can be used for the targeting of proteins or
cells for various fundamental and applied applications.37,48–51
In this work, we aimed to combine both approaches and
show the impact on the binding of multivalent glycomimetics to
Gal-3 (Fig. 1). First, we applied our previously introduced solid
phase assembly of tailor-made building blocks to obtain
monodisperse, sequence-controlled glycooligoamides, so-called
precision glycomacromolecules, presenting carbohydrate frag-
ments identied as ligands of Gal-3.52–56 To test for the inuence
of the scaﬀold structure on the lectin binding, glyco-
macromolecules were synthesized varying the overall valency
and distance between individual carbohydrate ligands and inFig. 1 Schematic representation of assembling glycofunctionalized
liposomes using solid phase synthesis of precision
glycomacromolecules.
This journal is © The Royal Society of Chemistry 2019the length of the linker attaching ligands onto the scaﬀold
(Fig. 2). Selected glycomacromolecules were then conjugated to
lipids and the resulting ligand–lipid conjugates were used in
liposome formulations. With this approach, we incorporate
multivalency on two levels: the presentation of multiple lactose
ligands along the macromolecular scaﬀold followed by the
multiple presentation of the glycomacromolecules on the lipo-
some (Fig. 1).
Percec and co-workers used carbohydrate-functionalized
dendrimers to incorporate multiple mono- or divalent
constructs into liposomes and study the eﬀects on clustered
ligand presentation.25 Ratner and co-workers showed the
incorporation of multivalent mannose- and galactose-
functionalized polymers into liposomal formulations and the
use of such glycopolymer-augmented liposomes to elucidate
receptor-mediated uptake inmacrophages.57While they showed
that the use of glycopolymers allowed for higher selectivity and
specicity of cellular uptake of the glycoliposomes, they did not
compare the eﬀects of multivalent presentation of single
ligands vs. multivalent glycopolymers on the liposomes. Such
‘multivalency of multivalency’ glycostructures are well-known in
nature, e.g. the glycolipids or glycoproteins. Our synthetic
platform allows for the systematic build-up of such structures
starting from individual building blocks and building to
multiple levels of multivalency (Fig. 1). This provides us with
model compounds to study whether these two kinds of
presentation in the glycomacromolecule–lipid conjugates are
simply additive or benet from additional factors. In this study,
the binding to Gal-3 of both glycomacromolecules and
glycomacromolecule-functionalized liposomes with variations
in the number and spacing of carbohydrate ligands along the
scaﬀold is investigated in inhibition-competition studies using
an enzyme-linked immunosorbent inspired-assay (ELISA) and
surface plasmon resonance (SPR).
Results and discussion
Synthesis of glycomacromolecules and glycomacromolecule–
lipid conjugates
Synthesis of glycomacromolecules 1–10 and 12–16 was accom-
plished by applying a previously established solid phase polymer
strategy (Fig. 2).52,56,58 In short, building blocks bearing a carbox-
ylic acid and an Fmoc-protected amine group were coupled to an
amine functionalized resin using PyBOP and DIPEA for activa-
tion. Aer successful coupling, Fmoc-deprotection with piperi-
dine released the N-terminus of the rst building block which
could then be used for coupling of the next building block. This
stepwise assembly allows for the synthesis of monodisperse,
sequence-controlled oligomers. For the synthesis of glyco-
macromolecules in this study, TDS (triple bond diethylenetri-
amine succinyl, 1-(uorenyl)-3,11-dioxo-7-(pent-4-ynoyl)-2-oxa-
4,7,10-triazatetra-decan-14-oic acid)52 was used as an alkyne-
functionalized building block for later conjugation with azide-
derivatives of diﬀerent carbohydrate ligands via copper(I)-cata-
lyzed alkyne–azide cycloaddition (CuAAC). EDS (ethylene glycol
diamine succinyl, 1-(9H-uoren-9-yl)-3,14-dioxo-2,7,10-trioxa-
4,13-diazaheptadecan-17-oic acid)59 was chosen as a spacerRSC Adv., 2019, 9, 23484–23497 | 23485
Fig. 2 Overview of synthesized glycomacromolecules: (a) galactose-functionalized structures 1–3, (b) lactose-functionalized structures 4–12,
(c) propyl lactose-functionalized structures 13–15, (d) glucose-functionalized structure 16. Structures denoted with *were synthesized as amine





























































































View Article Onlinebuilding block introducing an ethylene glycol motif in the main
chain of the glycomacromolecules. Through diﬀerent combina-
tions of these building blocks, glycomacromolecules with varying
numbers of carbohydrate ligands and diﬀerent spacing between
ligands along the oligomeric scaﬀold were obtained (Fig. 2). b-
Galactose (Gal) and b-lactose (Lac) were applied as known
binding ligands of Gal-3. To investigate the eﬀect of the linker
between the carbohydrate ligand and the oligomeric scaﬀold, two
diﬀerent lactose-derivatives were conjugated, one with an
anomeric azide, and one with a propyl linker terminating in an
azide (Fig. 2). Finally, a non-binding a-glucose (Glc) residue was
used to prepare glucose-functionalized glycomacromolecules as
negative controls. All carbohydrate ligands were conjugated on
solid support using previously reported conditions for CuAAC.60Fig. 3 Synthesis of lipid-conjugate L4 through the reaction of DSPE-PE
23486 | RSC Adv., 2019, 9, 23484–23497De-O-acetylation of the carbohydrate residues under Zempl´en
conditions and cleavage from solid support gave the nal glyco-
macromolecules.61 All structures were then puried by ion
exchange and preparative HPLC to obtain nal structures with
high purities $ 95% (determined by UV 214 nm signal of RP-
HPLC) (see ESI†).
In contrast to glycomacromolecules 1–10 and 12–16,
compound 11was prepared in solution. Diethylenetriamine was
treated with 4-pentynoyl chloride resulting in the precursor TPD
18 (tripentynoic acid diethylene triamine, N,N-bis(2-(pent-4-
ynamido)ethyl)pent-4-ynamide) (Fig. 2). This was followed by
conjugation of an azido-lactose analog via CuAAC (Scheme S1†).
Global deprotection using Zemple´n transesterication, fol-
lowed by neutralization with Amberlite IR120 resin andG-NHS and glycomacromolecule Lac(1)-2 (4*).
This journal is © The Royal Society of Chemistry 2019





[M + Na]+ m/z found
L4 C173H330N11O73PNa 3786.5 3787.8 66/58
L9 C243H446N27O107PNa 5511.3 5511.6 56/44
L10 C223H410N23O99PNa 5051.8 5052.4 66/69
L16 C231H428N27O95PNa 5158.0 5158.7 62/35
a MALDI-TOF-MS measurements were performed using positive ion mode. Molecular weights were calculated for the monitored maximum peak
with a PEG repetition unit of 44. b Conversion ratio of conjugated lipid was determined by 1H-NMR via integration of the terminal methyl
groups of the lipid chains signal normalized to the anomeric proton of the carbohydrate. c Determined by balance weight considering the
conversion.
Table 2 Dynamic light scattering and zeta potential analysis of the
liposomes L4, L9, L10 and L16
Glycomacromolecule–
lipid-conjugate used Diameter (d)a [nm] PDIb Zeta potentialc [mV]
L4 156  15 0.010 23.1  7.6
L9 150  16 0.011 16.9  8.5
L10 154  29 0.035 19.6  8.2
L11 146  29 0.039 16.9  8.5
a Diameters (d) were determined by DLS analysis of the liposome
solution. b PDI were determined via Gaussian t of the DLS curve
giving the standard deviation s and applying PDI ¼ (s/d)2. c Zeta





























































































View Article Onlinepreparative HPLC yielded Lac3TPD 11 with a purity $ 95%,
determined by RP-HPLC. All nal products were analyzed using
1H-NMR spectroscopy, analytical HPLC coupled with ESI-MS
and HR-MS analysis (for more information see ESI†). Nomen-
clature of the nal glycomacromolecules includes information
on the type and position of the carbohydrate residue, as well as
the overall valency of the oligomer. For example, Lac(1)-2, 4,
represents a monovalent structure bearing a Lac ligand on the
rst position of a dimeric structure and Lac(1,5)-5 L, 14, is
a divalent structure containing propyl linked (L) Lac in position
1 and 5 of a pentameric scaﬀold.
For the glycomacromolecule–lipid conjugation and later
functionalization of the sensor surface for SPR measurements,
amine functionalized glycoconjugates 4*, 9*, 10* and 16* were
synthesized. For these derivatives, CuAAC was performed on
scaﬀolds containing a terminal Fmoc group instead of the usual
acetyl group. This was, followed by Fmoc-cleavage with piperi-
dine and deprotection of the carbohydrates. Aer cleavage, the
amine functionalized glycomacromolecules were puried via
preparative chromatography resulting in purities $ 95%, as
determined by RP-HPLC (see ESI†).
Lipid conjugation was conducted according to a previously
published protocol.62 Commercially available DSPE-PEG-NHS
ester was used as lipid (Fig. 3). The conjugation reaction was
performed in amixture of DMF and NaHCO3 aq (1/10) overnight.
Aer removal of the solvents, the lipid-conjugates were puried
by dialysis against buﬀer and water. Aer lyophilization, the
products were analyzed by 1H-NMR spectroscopy and MALDI-
TOF-MS. The results are summarized in Table 1.
Reaction conversions, equivalent to the ratio of conjugated
lipid, were determined by 1H-NMR via integration of the
terminal methyl groups of the lipid chains normalized to the
anomeric proton of the carbohydrate moieties. They were found
to be between 56–66%, which could be due to hydrolysis of the
NHS-ester group of DSPE-PEG-NHS in aqueous solution. This
hypothesis is strengthened by the MALDI-TOF-MS analysis,
showing a corresponding MS-signal (see e.g. Fig. S69†) of the
hydrolysis product of DSPE-PEG-NHS. For liposome formula-
tion, the ratio of conjugated to unconjugated lipids was taken
into account in order to obtain similar numbers of carbohydrate
ligands per liposome.This journal is © The Royal Society of Chemistry 2019Liposome preparation
For the liposome formulation, DSPC was used as the main lipid
component with cholesterol as an additive for membrane
stabilization through reduction of lipid ordering and increased
melting temperatures (Fig. S1†).63–65 This liposomal formulation
is approved by the FDA and therefore regularly used as standard
in pharmaceutical research.66 The glycomacromolecule–lipid
conjugates were used in a total quantity of 4.75 mol% in the
whole formulation.
Lipid lm hydration and extrusion were used for the prep-
aration of the liposomes. Extrusion allowed for size adjustment
and homogenization. The liposomes were analyzed with DLS
showing diameters (d) of approximately 150 nm and poly-
dispersity indices (PDI) between 0.010–0.039. Vesicles in this
PDI-range are termed monodisperse.67,68 Zeta potentials were
measured to verify the negative charge of the surface, which
correlates with the successful incorporation of the glyco-
macromolecule–lipids, and the overall stability of the lipo-
somes. The results of the DLS and zeta potential measurements
are summarized in Table 2 and correspond well to comparable
systems in literature.50,62 Measurements were repeated aer
three months and showed comparable results indicating the
stability of the liposomes over time (data not shown).
Considering the incorporated glycomacromolecules could
theoretically be presented on the inner or outer surface of the
liposomes, the concentration of lactose, which can interact withRSC Adv., 2019, 9, 23484–23497 | 23487
Table 3 Inhibition constants (IC50 values), relative inhibitory potencies (RIP), RIP per glycan and inhibitory potencies (IP) for Lac and glyco-
macromolecules 4–15
Glyco-conjugate No. of carbohydrate IC50  SDa [mM] RIPb RIP/Lac IPc [%]
Lactose 1 159  13 1.0 1.0 —
Lac(1)-2, 4 1 123  3 1.3 1.3 31
Lac(2)-3, 5 1 111  4 1.4 1.4 46
Lac(1,5)-5, 6 2 55  5 2.9 1.5 61
Lac(1,5,9)-9, 7 3 36  3 4.4 1.5 66
Lac(1,4,7)-8, 8 3 42  3 3.8 1.3 65
Lac(1,3,5)-6, 9 3 38  2 4.2 1.4 68
Lac(1,2,3)-4, 10 3 37  1 4.3 1.4 72
Lac3-TPD, 11 3 29  1 5.5 1.8 77
Lac(1,2,3,4,5,6)-7, 12 6 16  4 9.8 1.6 78
Lac(2)-3 L, 13 1 133  8 1.2 (0.8*) 1.2 36
Lac(1,5)-5 L, 14 2 87  3 1.8 (0.6*) 0.9 50
Lac(1,5,9)-9 L, 15 3 50  2 3.2 (0.7*) 1.1 55
a Determined by ELISA-inspired inhibition studies on ASF coated plates. Measurements were performed two times in triplicates. b Relative
inhibitory potency normalized to IC50 value of Lac (159 mM).
c Reduced IC50 experiment determined by SPR inhibition studies with 100 mg mL
1
Gal-3 in PBS and 50 mM ligand. Binding signal of blank Gal-3 was set to 100% binding and 0% inhibition, inhibition values reported are





























































































View Article OnlineGal-3 in binding studies, was determined with a lactose-assay
kit from BioAssay Systems.69,70 Here, the use of sterically
demanding enzymes allows for the discrimination of the
carbohydrates presented on the outer vs. the inner surface of
the liposomes. Lactase is used to degrade Lac into Glc and Gal
and the Gal concentration is determined indicating the
concentration of accessible Lac. In contrast to the standard
protocol, Lac was not a suitable standard because of the time-
dependent behavior of free Lac hydrolysis compared to the
conjugated Lac on the liposomes (see Fig. S2†). One reason for
the observed discrepancy could be that the lactase converts the
free Lac in solution more slowly than the Lac on the liposome
surface, which also has been observed for other enzyme–
substrate systems.71 Therefore, Gal was used instead of Lac as
an alternative standard. An additional deviation from the
protocol involved incubation of the samples with lactase only in
assay buﬀer for 24 hours at 37 C prior to dye-incubation
instead of mixing the sample directly with lactase and dye-
reagent simultaneously to achieve full degradation of lactose
to its monosaccharides galactose and glucose. To verify the
stability of liposomes during the measurements, 20 mL of theTable 4 Inhibition constants (IC50-values), relative inhibitory potency (
functionalized liposomes L4, L9, L10
Glycoconjugate No. of carbohydrate Cmeas.  SDa [mM] (Cme
Lac(1)-2, 4 1 —
Lac(1,3,5)-6, 9 3 —
Lac(1,2,3)-4, 10 3 —
Lac(1)-2, L4 1 143  19 (94)
Lac(1,3,5)-6, L9 3 127  18 (94)
Lac(1,2,3)-4, L10 3 107  18 (66)
a Cmeas. [mM]: concentration of the glycomacromolecules on the liposome
relative to the theoretical concentration (Coligo/C100% [%])).
b Determined b
were performed two times in triplicates. c Relative inhibitory potency (RI
compared to the corresponding single ligand in solution.
23488 | RSC Adv., 2019, 9, 23484–23497liposome–enzyme mixtures were diluted aer the assay to
a total volume of 1 mL with ultrapure water and measured with
DLS. PDI and liposome diameter were in the pre-assay range
indicating that the liposomes were stable during the assay (data
not shown). Results from this protocol gave the surface
concentration of Lac as shown in Table 4. Considering the
amount of glycoligand–lipid-conjugate, which was used for the
liposome formulation, the percentage of ligand on the liposome
surface was calculated to be 94% for both L4 and L9 and 66%
for L10.Galectin-3 binding studies
Binding of glycomacromolecules and liposomes to Gal-3 was
evaluated by an inhibition competition study using an ELISA-
inspired assay as previously introduced by Elling and co-
workers72 and commonly used when evaluating the binding of
glycomimetic structures to galectins.73–75 Asialofetuin, a natural
multiantennary glycoprotein presenting nine terminal LacNAc
residues, was coated onto microplates to enable the binding of
Gal-3.76 Diﬀerent concentrations of glycomacromolecules wereRIP) of the glycomacromolecules 4, 9, 10 and glycomacromolecules
as./C100% [%]) IC50  SDb [mM] RIPc RIPligand/liposomed
123  3 1.3 —
38  2 4.2 —
37  1 4.3 —
12  2 13 10
1.0  0.1 161 38
0.3  0.03 482 112
surface determined with the lactose assay (percentage of glycooligomer
y ELISA-inspired inhibition studies on ASF coated plates. Measurements
P) normalized to IC50 value of lactose (159 mM).
d RIP of the liposomes





























































































View Article Onlineadded to the plates followed by Gal-3 carrying a His (histidine)-
tag to achieve a competition event. Residual Gal-3/asialofetuin
binding was then determined using a His-tag antibody
carrying horseradish peroxidase (HRP) for the conversion of
tetramethylbenzidine (TMB). Aer stopping the reaction by
addition of HCl, absorbance was quantied at 640 nm. Inhibi-
tion of Gal-3 was determined by observing a decreasing signal in
dependence of the ligand concentration.
Plotting of the binding signal of Gal-3 against the ligand
concentration gives inhibition curves as shown in Fig. 4a (for
more information see ESI†). From these curves, the half
maximal inhibition concentrations (IC50 values) could be
determined. For the relative inhibitory potency (RIP), the ob-
tained IC50 values were normalized to the IC50 value of non-
conjugated Lac. Thus, stronger binding to Gal-3 results in
a lower IC50 value and a higher RIP. To evaluate eﬀects of va-
lency further, the RIP was normalized to the number
of carbohydrates per glycomacromolecule giving the RIP/Lac.
The IC50 values and relative inhibitory potencies (RIP) as well
as the RIP normalized to carbohydrate moieties for ligands 4–15
are listed in Table 3. Binding studies with galactose structures
1–3 (Fig. S4†) and the negative control 16 (Fig. 3) did not show
any signicant inhibition. Gal is known to be a poor binder forFig. 4 Results from the inhibition of Gal-3 in an ELISA-inspired assay. (a) E
and negative control 16. Values are normalized to the signal of pure Ga
comacromolecules 4, 6, 10 and 12 with increasing valency; (c) glyc
macromolecules 5–7 and their propyl-Lac counterparts 13–15. RIP are
This journal is © The Royal Society of Chemistry 2019Gal-3 with Kd values around 10mM,77 50-fold lower compared to
the disaccharide Lac with a Kd value of 0.2 mM.78 Thus, the
multivalent presentation of Gal on the macromolecular scaﬀold
did not lead to a suﬃcient increase in binding to eﬃciently
inhibit Gal-3 in this assay.
In general, a decrease in IC50 values and a corresponding
increase in RIP values indicates an increase in inhibitory
potency and thereby presumably binding aﬃnity. For Lac
structures 4–15, slightly increased inhibitory potencies are
observed for glycomacromolecules with increasing valency
(number of Lac residues) and decreasing spacing (number of
EDS building blocks in between Lac-functionalized building
blocks) (Fig. 4b and c). For the trivalent ligands showing the
same valency and linker length, the lowest IC50 value was
observed for the smallest ligand of this series, glyco-
macromolecule 11, with 29  1 mM, and the highest IC50 value
was observed for one of the largest structures, glyco-
macromolecule 8, with 42  3 mM. An explanation could be in
the sterical and geometrical eﬀects related to the distances
between the carbohydrate-epitopes which can have an impact
on protein-clustering. Considering the distances of the N-atoms
of the three triazoles in the stretched trivalent structures, the
smallest structure Lac3TPD 11 was found to have theoreticalxemplary inhibition curves of the inhibitionwith structures 4, 8, 9, 10, 11
l-3. (b–d) IC50 values [mM] (black) and RIP (grey) for: (b) Lac and gly-
omacromolecules 4, 8–11 with decreasing spacing and (d) glyco-
referenced to the IC50 value of lactose.





























































































View Article Onlinedistances between 8–17 A˚, whereas the glycomacromolecule 8
was found to be in a range of 44–87 A˚ (see ESI Fig. S9 and S10†).
To the best of our knowledge, the distances between the
CRDs in oligomeric Gal-3 lattices have not yet been reported,
and are likely to vary signicantly based on their complexity and
exible geometry.79 The results of the spacing are strengthened
by studying the inuence of the linker length and the distance
of the triazole moiety from the carbohydrate on the inhibition of
Gal-3 as shown in Fig. 4d. When comparing compounds 5–7
and 13–15, we observe that the introduction of a longer linker
between the lactose ligand and oligomer backbone leads to
a decrease in binding showing just 0.6–0.8 relative potency
when compared to their shorter linker counterparts (Table 3,
marked with *). This eﬀect is even more pronounced with the
higher valent glycomacromolecules.
We hypothesize the diﬀerences in avidity could also be due
in part to the triazole motif in the linker participating in
hydrophobic interactions in the binding groove of Gal-3. Similar
results were found by Nilsson and co-workers where replacing
ester or amide bonds through triazoles had an impact on the
aﬃnity and specicity towards Gal-3.80 In addition, the inu-
ence of hydrophobic, aromatic residues such as triazole,
substituted phenyl and coumaryl methyl on the binding of Gal-3
is well-known from literature and might also eﬀect binding of
the glycomacromolecules.16,33,81–83
Besides geometrical eﬀects and hydrophobic interactions,
entropy can also play an important role where the loss of exi-
bility due to increased rigidity can have a positive impact on the
entropy of the system.84,85 In this study, Lac3TPD 11 is assumed
to be the most rigid structure showing the highest avidity
towards Gal-3 in comparison to the other trivalent systems.
Pieters and co-workers performed solid phase inhibition and
uorescence polarization studies on rigidied multivalent
lactose ligands where they could see a twofold higher binding of
rigidied structures compared to their more exible counter-
parts.19 Furthermore, they could observe a high multivalent
eﬀect with increasing valency showing a 300 times higher
binding for a tetravalent structure with a IC50 value of 0.07 mM
compared to the monovalent derivative with an IC50 value of 21
mM and free lactose with 300 mM.19 In our case, the monovalent
glycomacromolecules 4 and 5 show only slightly increased
binding by a factor of 1.3–1.4 in comparison to free Lac, whereas
the highest increase was observed for hexavalent ligand 12 by
a factor of about 9–10. Comparing the characteristics of the
herein reported glycooligo(amidoamines) and the discussed
rigidied lactosidic structures, the more aromatic and thus
hydrophobic nature of the structures by Pieters could be the
reason for the more distinguished enhancement in binding,
caused by participation of the aromatic residues on the binding
event as mentioned before.
Overall, looking at all examined structures, the relative
increase in inhibition for the glycomacromolecules is compa-
rable to other multivalent constructs of similar valencies from
literature, though not as potent as the previously discussed
study by Pieters.19 In another example, Cagnoni and co-workers
observed relative potencies of 10 and 6 by presenting dithio-
galactose as di- and tetrasaccharides in comparison to the23490 | RSC Adv., 2019, 9, 23484–23497monovalent analogues.86 The aforementioned glycoclusters
synthesized by Gabius and Roy evaluated in a solid-phase assay
resulted in IC50 values of 165 mM for the divalent structure
compared to 62–125 mM for the tetravalent structures.
Compared to free lactose with 700 mM, the divalent structure
showed an RIP of 4.3 and the tetravalent 5.6–11.2, which is
again in the same range or even lower than those reported here
from glycooligo(amido amines).30
In general, the obtained IC50 values of the glyco-
macromolecules are within the concentration range expected
for this type of ELISA-inspired inhibition study on Gal-3. For
example, Elling and co-workers reported IC50 values between 6
and 42 mM for LacNAc-based di- to heptasaccharides, respec-
tively.73 Notably, LacNAc is an even better binder for Gal-3 with
a Kd of 70 mM.72
SPR was used to perform a reduced IC50 experiment as
a comparable method to support the aforementioned ELISA-
inspired assay. Trivalent ligand Lac(1,3,5)-6 (9*) with
a terminal amine group was used for sensor surface function-
alization to provide high loading. The experimental conditions
were based on the results from the ELISA study. In this case
a xed concentration of Gal-3 (100 mg mL1) and a xed
concentration of ligands (50 mmol L1) were used. Comparing
Gal-3 binding in presence of the diﬀerent ligands gives the
inhibition potency (IP) at xed ligand and receptor concentra-
tions. In this context, higher aﬃnity ligands result in a lower
Gal-3 binding signal (Fig. 5 and ESI†) and higher IP values
(Table 3).
SPR measurements (Fig. 5) support the results and trends
observed in the ELISA-inspired assay (Fig. 4). Decreased
spacing, e.g. going from structure 7 to 11, led to a slight increase
in inhibitory potency from 65% to 77% (Table 3). Structures
with the longer propyl-based linker 13–15 again showed lower
inhibitory potency compared to derivatives 5–7 with the shorter
linker.
Based on these ndings, lipid-conjugation was performed
with two trivalent ligands with diﬀerent spacing and overall size
(9* and 10*) as well as a monovalent glycomacromolecule (4*).
As a negative control, a trivalent Glc-functionalized glyco-
macromolecule (16*) of the same sequence as Lac-
functionalized ligand (9*) was included. The inhibitory
potency of the liposomes (L4, L9 and L10) were studied by the
same ELISA-inspired assay previously used for the free ligands
(Fig. 4).
To compare results based on the number of Lac ligands
available for binding to Gal-3 on the surface of the liposomes,
IC50 values were normalized to the concentration of Lac as
determined by the lactase-assay described above. To further
compare the inhibitory potency of the ligands attached to the
liposomes vs. the free ligands in solution, IC50 values were
normalized to the IC50 value of Lac giving the RIP of the lipo-
somes (Fig. 6).
To better demonstrate and compare the avidity enhance-
ment enabled through the presentation of the glyco-
macromolecules on the liposomes, the RIPs of the
glycomacromolecules were divided by the RIPs of the corre-
sponding liposomes giving the RIPligand/liposome (Table 4).This journal is © The Royal Society of Chemistry 2019
Fig. 5 Results from the reduced IC50 SPR inhibition experiment of Gal-3 with samples 4–15. (a) Exemplary SPR-sensorgrams of only Gal-3 and
Gal-3 incubated with macromolecule 4, 8–11. (b and c) Gal-3 binding signal  SD [%] with reference of only Gal-3 signal as 100% binding for (b)
glycomacromolecules 4, 6, 10 and F with increasing valency; (c) glycomacromolecules 4, 8–11 with decreasing spacing and (d) glyco-





























































































View Article OnlineResults show the same trends for the diﬀerent ligands pre-
sented on the liposomes in comparison to the free ligands, with
the smaller trivalent structure (L10) showing a slightly higher
inhibition potency than the longer trivalent ligand (L9), and
trivalent ligands showing higher inhibition potency than the
monovalent ligand (L4). Negative control L16 showed no
inhibitory eﬀect on Gal-3 binding (Fig. 6).
To support the results of the ELISA, the liposomes were
tested in the reduced IC50 assay using SPR as previously
described for the glycomacromolecules. However, using the
same concentration of liposomes as the free glyco-
macromolecules led to complete inhibition of Gal-3 (data not
shown). Reducing the concentration to 10 mM yielded detect-
able diﬀerences in Gal-3 binding (see sensorgrams shown in
Fig. 6). Results of the ELISA were again supported with smaller
and higher valent structures showing higher binding.
Comparing the IC50 values of the liposomes with the corre-
sponding inhibition of the glycomacromolecules revealed that
presentation on the liposome surface leads to an increase in
inhibitory potencies. For the best binder of the liposomal
formulations (L10), inhibition potency increases 112-fold from
37 to 0.3 mM in comparison to the free ligand 10. This is in the
order of magnitude for a comparable ‘multivalency of multi-
valency’ system from the work of Laaf and co-workers whoThis journal is © The Royal Society of Chemistry 2019observed 180 to 350-fold higher inhibition for diﬀerent
saccharides presented in a multivalent fashion on BSA
compared to the free saccharide in solution.35,36 In addition, the
glycodendrimers evaluated by Gabius and Roy presenting 90
lactose residues showed IC50 values of 0.16 mM compared to 164
mM for the monovalent ligand, resulting in an inhibitory
potency of 1025 and 11 per carbohydrate.31
Several studies suggest that Gal-3 oligomerizes upon glycan
binding through its N-terminal domain,29,32,87 however, CRD
mediated multimerization has also been described.88–90 With
multivalent glycans on cell surfaces, Gal-3 can induce cell–cell
interactions, crosslink receptors and even form lattice on cell
surfaces.29,79 Due to the complexity and exibility of galectin
oligomers an increase in inhibitory potential can also point
towards the formation of larger aggregates with Gal-3 based on
the crosslinking property of galectin oligomers. This has been
demonstrated for Gal-3 induced glycodendrimers24 and glyco-
dendrisomes.25–29 Lactose was used as relative low aﬃnity glycan
and induced aggregation as multivalent ligand through Gal-3
binding. Interesting in our study is that the presentation of
lower aﬃnity monovalent ligand 4 and the trivalent ligand 9 on
the liposomes (L4, L9), led to an increase of 10-fold or 38-fold,
respectively. This shows that both the multivalency of the gly-
comacromolecules as, well as the multivalency of theRSC Adv., 2019, 9, 23484–23497 | 23491
Fig. 6 Results of the inhibition studies of the liposomes L4, L9, L10 and L16. (a) Inhibition curves of the inhibition of Gal-3 in ELISA-inspired assay.
(b) Resulting IC50 values and RIP. Results from the reduced IC50 SPR inhibition experiment of Gal-3 (100 mg mL
1) and 10 mM of L4, L9, L10 and
L16. (c) Exemplary SPR sensorgrams of only Gal-3 and incubated with L4, L9, L10 and L16. (d) Gal-3 binding signal SD [%] with reference of only





























































































View Article Onlinepresentation on the liposomes, contribute to the increased
binding of Gal-3. Whether Gal-3 oligomerizes and forms
aggregates with multivalent liposomes remains to be studied in
future work.Conclusions
Within this work, we investigated eﬀects of the multivalent
presentation of Lac using precision glycomacromolecules in
binding to Gal-3. The use of solid phase synthesis allowed
for the controlled variation of carbohydrate valency, spacing
and linkage on an oligo(amidoamine) scaﬀold. ELISA-
inspired and SPR assays revealed an inuence of all three
parameters on Gal-3 inhibition giving inhibition constants
in the lower mM range. As expected, higher valency leads to
higher binding. Surprisingly, decreasing the linker length
and overall size of the scaﬀold also leads to an increase in
binding. We partially attribute this to secondary binding
interactions of the hydrophobic triazole linkages which are
in closer proximity to the lectin for glycomacromolecules
with shorter linkers. Further conjugation of selected glyco-
macromolecules to lipids allowed for additional multivalent23492 | RSC Adv., 2019, 9, 23484–23497presentation on the surface of liposomes, which increased
binding and resulted in nM inhibition. However, the
presentation of monovalent ligands in the liposomal
formulations resulted in a much less pronounced increase
in inhibitory potency, showing the importance of multi-
valency on both length scale, the macromolecular scaﬀold
and liposome decoration, to eﬀectively yield high avidity
ligands. Indeed, this is a key feature of many glyco-
conjugates in nature such as glycolipids or glycoproteins.
Our synthetic platform and the approach presented here
give straightforward access to the design and synthesis of
ligands using ‘multivalency of multivalency’ eﬀects to ach-
ieve high avidity biomimetic ligands and to further study the
underlying mechanisms involved in receptor binding and
clustering.Experimental
Materials
All reagents and solvents were used without further purica-
tion. Acetic anhydride and sulfonic acid were purchased from





























































































View Article Onlinemethoxide, pentynoic acid and sodium diethyldithiocarbamate
were purchased from Acros Organics. Dimethylformamide (for
peptide synthesis) was purchased from Biosolve. Triisopro-
pylsilane (TIPS) was purchased from Sigma Aldrich. Oxalyl
chloride was purchased from Alfa Aesar. HOBt was purchased
from Iris Biotech. N,N-Diisopropylethylamine (DIPEA) and
diethylenetriamine were purchased from Carl Roth. Sodium
ascorbate, phenol and potassium carbonate were purchased
from PanReac AppliChem. Dichloromethane and triethylamine
were purchased from Merck. PyBOP was purchased from Fluo-
rochem and CuSO4 anhydrous from Fluka Chemika. Phosphate-
buﬀered saline (PBS) tablets were purchased from Sigma
Aldrich and ready-made PBS buﬀer from Gibco.
Solid phase synthesis was performed on TentaGel® SRAM
resin purchased from Rapp Polymere using polypropylene
reactors with polyethylene frits closed with Luer-stoppers from
MultiSyntech GmbH. Ion exchange resin AG1-X8, quat. ammo-
nium, 100–200 mesh, acetate form was purchased from BioRad
and Amberlite IR120 (hydrogen form) from Sigma Aldrich. For
the liposomes, 1,2-distearoyl-sn-glycero-3-phosphocholine ¼
COATSOME MC-0808® (DSPC), N-(methylpolyoxyethylene oxy-
carbonyl)-1,2-distearoyl-sn-glycero-3-phosphoethanolamine
sodium salt¼ SUNBRIGHT DSPE-020CN (DSPE-PEG) and N-[N0-
(succinimidyloxy glutaryl)aminopropylpolyoxyethylene oxy-
carbonyl]-1,2-distearoyl-sn-glycero-3-phosphoethanolamine
sodium salt ¼ SUNBRIGHT DSPE-020GS (DSPE-PEG-NHS) were
purchased from NOF Europe. Cholesterol was purchased from
Sigma Aldrich. Filter supports and a Mini-Extruder Kit were
purchased from Avanti Polar Lipids and used with Hamilton-
syringes (1000 mL) with polycarbonate membranes, pore sizes
0.1 and 0.2 mm. Slide-A-Lyzer™ Dialysis Cassettes were
purchased from Thermo Scientic, ultrapure water was
supplied from Invitrogen™ UltraPure™ from FisherScientic.
EnzyChrom TM Lactose-Assay Kit was purchased from BioAssay
Systems and used together with a Multiskan Go Microplate
Spectrophotometer from Thermo Scientic and clear at-
bottom 96-well microplates from Greiner Bio-One.
(2-Azidoethyl)-2,3,4,6-tetra-O-acetyl-b-D-galactopyrano-
side, (2-azidoethyl)-2,3,4,6-tetra-O-acetyl-a-D-glucopyrano-
side and hepta-O-acetyl-b-lactosylazide were synthesized
following established protocols.91 Reactions were observed
via analytical thin layer chromatography, performed on
Merck silica gel 60 F254 plates and were visualized with
ninhydrin and anisaldehyde staining. 1H-NMR and 13C-NMR
spectra were measured on Bruker Avance III 300 or Bruker
Avance III 600. Analytical reversed phase HPLC (RP-HPLC)
measurements were performed on Agilent Technologies
6120 series coupled with an Agilent quadrupole mass spec-
trometer. All spectra were measured with solvent A: 95% H2O,
5% ACN, +0.1% formic acid, and solvent B: 5% H2O, 95%
ACN, +0.1% formic acid with a gradient of 5 to 50% B over
30 min. Purities of the compounds were determined by the
integration of the signals absorbing at 214 nm. Preparative
RP-HPLC was performed on an Agilent 1200 series. High
resolution ESI (HR-ESI) spectra were measured on UHR-
QTOF maXis 4G (Bruker Daltonics).This journal is © The Royal Society of Chemistry 2019Methods
Solid phase synthesis. Solid phase synthesis of glyco-
oligoamides was performed as reported.52 General protocols for
the solid phase synthesis are described for batch sizes of
0.1 mmol as total loading of the resin. All reactions were per-
formed at room temperature in a reactor with a frit on a shaker.
Resin preparation and Fmoc cleavage. The resin (0.1 mmol,
400 mg, resin loading 0.25 mmol g1) was transferred into
a 10 mL reactor and 5 mL DCM were added to swell the resin for
1 h. Aer washing the resin 10 times with 5 mL DMF, the Fmoc
protecting group was cleaved by adding 5 mL of 25% piperidine
in DMF and shaking three times for 10 min. In between the
deprotection steps, the resin was washed three times with 5 mL
DMF, and aer the last deprotection, the resin was washed ten
times with 5 mL DMF.
Building block coupling. The building block (0.5 mmol, 5 eq.
to total loading of resin) and PyBOP (0.5 mmol, 260 mg, 5 eq.)
were dissolved in 3mL DMF and DIPEA (1mmol, 0.2 mL, 10 eq.)
was added. Aer ushing the solution with nitrogen for 1 min,
the solution was added to the resin and the reaction was shaken
for 1–1.5 h. Aer that, the liquid content was discarded and the
resin was washed ten times with 5 mL DMF.
Terminal-NH2 capping. The resin was treated with 3 mL
acetic anhydride two times for 15min. In between, the resin was
washed with 3 mL DMF 3 times. Aer the last capping step, the
resin was washed ve times with 5 mL MeOH and ve times
with 5 mL DMF.
Copper-catalyzed alkyne azide cycloaddition conjugation.
Carbohydrate azide derivative (3 eq./alkyne) was dissolved in
2 mL DMF. Separately, CuSO4$5H2O (50 mol%/alkyne) and
sodium ascorbate (50 mol%/alkyne) were each dissolved in
0.2 mL MilliQ water. The carbohydrate solution was rst added
to the resin, followed by sodium ascorbate and CuSO4. Aer
shaking the reaction mixture overnight, the resin was washed
sequentially with 5 mL of DMF, a solution of 0.2 M sodium
diethyldithiocarbamate in DMF and water (1/1), water, DMF
and DCM until no more color changes were monitored.
Carbohydrate deprotection. The resin was treated two times
for 30 min with 5 mL 0.2 M NaOMe in MeOH. In between, the
resin was washed three times with 5 mL MeOH, then the resin
was washed ve times with 5 mL of eachMeOH, DMF and DCM.
Macro cleavage. The resin was washed ten times with 5 mL
DMF and DCM. A cleavage solution consisting of 5 mL of 95%
TFA, 2.5% TIPS and 2.5% DCM was added to the resin, and the
reaction mixture was shaken for 1 h. The supernatant was
added dropwise to cooled Et2O (40 mL) to precipitate the
product. The mixture was centrifuged, the supernatant was
decanted, and the white precipitate was dried under a stream of
nitrogen. Aer dissolving the resulting solid in MilliQ water, the
solution was lyophilized.
In solution synthesis of Lac3TPD 11. 4-Pentynoic acid
(37 mmol, 3.6 g, 1 eq.) was dissolved in 90 mL DCM and oxalyl
chloride (37 mmol, 3.2 mL, 1 eq.) was added carefully. The
reaction was activated by a few drops of DMF and stirred for
1.5 h at room temperature. The resulting 4-pentynoic chloride





























































































View Article OnlineDiethylenetriamine (3 mmol, 0.3 mL, 1 eq.) was dissolved in
300 mL DCM and 4-pentynoic acid chloride (3 eq.) was added
carefully over 30 min. The reaction was stirred for 1 h at room
temperature. Aer adding 100 mL of a saturated NaHCO3
solution, the organic layer was separated, washed two times
with 50 mL of saturated NaHCO3 solution and dried over
Na2SO4. The solvent was removed under reduced pressure and
the crude product was recrystallized from ethyl acetate resulting
in the desired product 18 as a white solid in yield of 31%
(300 mg, 0.87 mmol).
TPD-precursor 18 (0.1 mmol 34 mg, 1 eq.) and azido-lactose
(0.45 mmol, 300 mg, 4.5 eq.) were dissolved in 2 mL DMF.
Sodium ascorbate (30 mg, 50 mol%/alkyne) and CuSO4 (38 mg,
50 mol%/alkyne) were each dissolved in 0.2 mL H2O and added
to the TPD-lactose solution. The mixture was stirred for 3 d at rt.
The reaction mixture was added to 40 mL H2O to precipitate the
product. Aer centrifugation, the precipitate was redissolved in
1 mL DMF and precipitated in 40 mL H2O for a second time.
The product was deprotected by treating the crude precipitate
with 6 mL of 0.2 M NaOMe in MeOH for 1 h. Aer adding 4 mL
H2O, the solution was neutralized using Amberlite IR120. Aer
ltration and removal of the solvent, the crude product was
puried using preparative RP-HPLC. The product was obtained
as a white solid with a yield of 50% (73 mg, 0.05 mmol).
Lipid-conjugation. DSPE-PEG-NHS (2 mg, 1 eq.) were dis-
solved in 100 mL DMF followed by the glycoligands 4*, 9*, 10*
and 16* (8 eq.) dissolved in 900 mL of 0.1 M NaHCO3 solution
and the solution was stirred overnight. Aer removing the
solvents under reduced pressure, the residue was redissolved in
1.5 mL 0.1 M NaHCO3 solution. The solution was dialyzed using
Slide-A-Lyzer cassettes with a molecular weight cut-oﬀ (MWCO)
of 7000 g mol1 rst three times for 8–12 h against 0.1 M
NaHCO3 and subsequently three times for 8–12 h against water.
The sample to solvent ratio was 1 mL to 250 mL up to 1 mL to
550 mL. Yields given in mg relate to the successfully conjugated
lipids. The content of unconjugated lipids was quantied via
1H-NMR and was excluded in the calculation.
Liposome formulation. Liposomes were prepared by the
hydration lm extrusion method.92 The general composition of
the liposomes was 57 mol% of DSPC, 38 mol% of cholesterol,
4.75 mol% of DSPE-PEG-ligand and 0.25mol%DSPE-PEG, or no
DSPE-PEG-ligand and 5 mol% DSPE-PEG for an unfunctional-
ized liposome. For the calculations of the DSPE-PEG-ligand, the
eﬀective molar mass was calculated taking into consideration
the mixture of conjugated and unconjugated DSPE-PEG-COOH
(through partially deactivated NHS) yielded from the conjuga-
tion step.
Stock solutions of each 8 mg mL1 DSPE-PEG and DSPE-
PEG-ligand in DMSO-d6, and 20 mg mL
1 DSPC and 10 mg
mL1 cholesterol in CDCl3 were prepared. The batch for the
formulation was calculated for a nal total lipid concentration
of 3 mmol in 624 mL PBS-buﬀer (4.81 mM).
All DMSO-dissolved compounds were added to a test tube
and the sample was freeze-dried. Then, DSPC and cholesterol
were added and the mixture was further dried in a stream of
nitrogen and subsequently under high vacuum for 1 h. 624 mL
PBS-buﬀer were added and the test tube was sonicated for four23494 | RSC Adv., 2019, 9, 23484–23497times at 50 C for 3–4 s, then vortexed and allowed to rest for
30 s. This procedure was repeated until all of the precipitate was
suspended.
In the following extrusion step, the extruder was build-up
and prepared as described by the supplier. The liposome
suspension was taken up with the Hamilton syringe of the mini-
extruder kit and was rst extruded 30 times through a 0.2 mm
lter and then through a 0.1 mm lter. The suspension was
allowed to stand for 30 min at room temperature and then
stored at 4 C.
Determination of the lactose concentration on the liposome
surface. The determination of lactose-concentration on the
liposome surface was conducted with the EnzyChrom™
Lactose-Assay Kit from BioAssay Systems. Changes to the
protocol included the following: (i) galactose was used as
a standard instead of lactose; (ii) the liposome samples were
rst incubated with 1 mL lactase in 28.3 mL assay buﬀer for 24
hours at 37 C; (iii) following incubation, the standard and
liposome samples were treated with 1 mL each of dye reagent
and enzyme mix in a total of 56.7 mL assay buﬀer. Subsequently,
all samples were incubated for 30 min at room temperature
before the optical density readout. The standards were prepared
in Eppendorf tubes to be able to vortex and shortly centrifuge
them before application onto the microplate. One stock solu-
tion of the lactase in assay buﬀer as well as enzyme mix plus dye
reagent in assay buﬀer was prepared for all tests of one
measurement together, carefully vortexed and subsequently
transferred to the microplate.
DLS and zeta potential. Dynamic light scattering (DLS) and
zeta potential measurements were performed with 20 mL of the
liposome suspension diluted with 980 mL of ultrapure water at
25 C. DLS was measured on a High Performance Sizer from
Malvern Instruments with polystyrene cuvettes and the ALV-
correlator soware Version 3.0 with a backscattering detector
(173) and 5 measurements per 30 s for each sample. Zeta
potential measurements were performed on a Zetasizer Nano Z
from Malvern Instruments with DTS1070 capillary cells.
Binding studies
Surface plasmon resonance. The SPR inhibition studies were
performed on a CM5 sensor chip on a Biacore X100 from GE
Healthcare Life Science. For immobilization, the “Surface
Preparation Wizard” for the sensor chip CM5 was used. The
functionalization of the two ow cells was performed through
an amine-coupling procedure with NHS/EDC (contact time
420 s, ow rate 10 mL min1). Flow cell 2 (mess cell) was
immobilized with 1 mM Lac(1,3,5)-6, 9*, in HBS-P buﬀer from
GE Healthcare with a contact time of 600 s. For ow cell 1
(reference cell) a blank immobilization with ethanolamine was
performed according to the soware. As running buﬀer, HBS-P
buﬀer from GE Healthcare was used. The immobilization levels
reached 411 RU for ow cell 2 and 186 RU for ow cell 1.
The inhibition assay was performed in a “Custom Assay
Wizard-Binding Analysis” in a multi cycle measurement. For the
inhibition studies, stock solutions of 200 mg mL1 of Gal-3 and
100 mM for each ligand in PBS buﬀer (150 mM NaCl, 50 mM
NaH2PO4, pH 7.5) were prepared. Gal-3 was incubated with each





























































































View Article Onlinea 1 : 1 ratio, resulting in nal concentrations of 100 mg mL1 for
Gal-3 and 50 mM for the ligands. The assay was performed with
PBS as running buﬀer using 90 s for association time and 60 s
for dissociation time with a ow rate of 10 mL min1 over both
ow cells. The cell surface was regenerated by injecting 3 M
MgCl2 in MilliQ water for 60 s with a ow rate of 10 mL min
1
over the surface aer each cycle. Liposomes were measured at
concentrations of 10 mM using a stock solution of 20 mM in PBS
buﬀer due to their higher binding aﬃnities to Gal-3.
The report points for the binding event of Gal-3 without and
with ligand were taken aer 155 s aer sensorgram adjustment
to baseline. The response unit of only Gal-3 was set as a refer-
ence point to 100% binding and 0% inhibition. Inhibition of
the glycomacromolecules were referred to the response unit of
only Gal-3. All measurements were performed in triplicates.
Enzyme-linked immunosorbent assay (ELISA). Inhibition
studies were performed according to an established protocol by
Elling and co-workers.35 Glycoligands 1–16 were measured with
nal concentrations between 0.1 and 2000 mM and liposomes
L4, L9, L10 and L16 with nal concentrations calculated
according to the results of the Lactose-Assay Kit between 0.002
and 14 mM of the glycoligands.
Conﬂicts of interest
There are no conicts to declare.
Acknowledgements
We thank Jan Dirks for his support in synthesizing the H2SO4-
cat. We acknowledge support by the Heinrich Heine University
Duesseldorf. We thank the Boehringer Ingelheim Foundation
for nancial support through the Plus 3 program and the DFG
for support through the large equipment grant INST 208/735-
1. L. E. and D. L. gratefully acknowledge nancial support by the
DFG (project EL 135/12-1).
References
1 D. H. Dube and C. R. Bertozzi, Nat. Rev. Drug Discovery, 2005,
4, 477.
2 H. Leﬄer, S. Carlsson, M. Hedlund, Y. Qian and F. Poirier,
Glycoconjugate J., 2002, 19, 433–440.
3 P. Nangia-Makker, J. Conklin, V. Hogan and A. Raz, Trends
Mol. Med., 2002, 8, 187–192.
4 A. C. F. Cardoso, L. N. d. S. Andrade, S. O. Bustos and
R. Chammas, Front. Oncol., 2016, 6, 1–12.
5 H. Blanchard, X. Yu, P. M. Collins and K. Bum-Erdene, Expert
Opin. Ther. Pat., 2014, 24, 1053–1065.
6 M. L. Bacigalupo, M. Manzi, G. A. Rabinovich and
M. F. Troncoso, World J. Gastroenterol., 2013, 19, 8831–8849.
7 H. Blanchard, K. Bum-Erdene, M. H. Bohari and X. Yu, Expert
Opin. Ther. Pat., 2016, 26, 537–554.
8 Y.-C. Chan, H.-Y. Lin, Z. Tu, Y.-H. Kuo, S.-T. Hsu and
C.-H. Lin, Int. J. Mol. Sci., 2018, 19, 392.
9 C. T. O¨berg, H. Leﬄer and U. J. Nilsson, Chimia, 2011, 65, 18–
23.This journal is © The Royal Society of Chemistry 201910 T. Funasaka, A. Raz and P. Nangia-Makker, Semin. Cancer
Biol., 2014, 30–38.
11 K. C. Haudek, K. J. Spronk, P. G. Voss, R. J. Patterson,
J. L. Wang and E. J. Arnoys, Biochim. Biophys. Acta, 2010,
1800, 181.
12 K. H. Mayo, in Galectins and Disease Implications for Targeted
Therapeutics, Am. Chem. Soc., 2012, vol. 1115, pp. 61–77.
13 L. D´ıaz-Alvarez and E. Ortega, Mediators Inammation, 2017,
9247574.
14 A. Lagana, J. G. Goetz, P. Cheung, A. Raz, J. W. Dennis and
I. R. Nabi, Mol. Cell. Biol., 2006, 26, 3181–3193.
15 J. Ochieng, M. L. Leite-Browning and P. Wareld, Biochem.
Biophys. Res. Commun., 1998, 246, 788–791.
16 V. L. Campo, M. F. Marchiori, L. C. Rodrigues and M. Dias-
Baruﬃ, Glycoconjugate J., 2016, 33, 853–876.
17 J. M. Cousin and M. J. Cloninger, Int. J. Mol. Sci., 2016, 17,
1566.
18 A. K. Michel, P. Nangia-Makker, A. Raz and M. J. Cloninger,
ChemBioChem, 2014, 15, 2106–2112.
19 I. Vrasidas, S. Andre´, P. Valentini, C. Bo¨ck, M. Lensch,
H. Kaltner, R. M. J. Liskamp, H.-J. Gabius and R. J. Pieters,
Org. Biomol. Chem., 2003, 1, 803–810.
20 Y. Hou, S. Cao, X. Li, B. Wang, Y. Pei, L. Wang and Z. Pei, ACS
Appl. Mater. Interfaces, 2014, 6, 16909–16917.
21 C. Lavilla, G. Yilmaz, V. Uzunova, R. Napier, C. R. Becer and
A. Heise, Biomacromolecules, 2017, 18, 1928–1936.
22 S. Andre´, C. E. P. Maljaars, K. M. Halkes, H.-J. Gabius and
J. P. Kamerling, Bioorg. Med. Chem. Lett., 2007, 17, 793–798.
23 C. E. P. Maljaars, S. Andre´, K. M. Halkes, H.-J. Gabius and
J. Kamerling, Anal. Biochem., 2008, 378, 190.
24 C. K. Goodman, M. L. Wolfenden, P. Nangia-Makker,
A. K. Michel, A. Raz and M. J. Cloninger, Beilstein J. Org.
Chem., 2014, 10, 1570–1577.
25 S. Zhang, R.-O. Moussodia, C. Murzeau, H.-J. Sun,
M. L. Klein, S. Ve´rtesy, S. Andre´, R. Roy, H.-J. Gabius and
V. Percec, Angew. Chem., Int. Ed., 2015, 54, 4036–4040.
26 C. Rodriguez-Emmenegger, Q. Xiao, N. Y. Kostina,
S. E. Sherman, K. Rahimi, B. E. Partridge, S. Li, D. Sahoo,
A. M. Reveron Perez, I. Buzzaccera, H. Han, M. Kerzner,
I. Malhotra, M. Mo¨ller, C. J. Wilson, M. C. Good,
M. Goulian, T. Baumgart, M. L. Klein and V. Percec, Proc.
Natl. Acad. Sci. U. S. A., 2019, 116, 5376–5382.
27 V. Percec, P. Leowanawat, H.-J. Sun, O. Kulikov,
C. D. Nusbaum, T. M. Tran, A. Bertin, D. A. Wilson,
M. Peterca, S. Zhang, N. P. Kemat, K. Vargo, D. Moock,
E. D. Johnston, D. A. Hammer, D. J. Pochan, Y. Chen,
Y. M. Chabre, T. C. Shiao, M. Bergeron-Brleck, S. Andre´,
R. Roy, H.-J. Gabius and P. A. Henry, J. Am. Chem. Soc.,
2013, 135, 9055–9077.
28 S. Zhang, Q. Xio, S. E. Sherman, A. Muncan, A. D. M. Rmaos
Vincente, Z. Wang, D. A. Hammer, D. Willams, Y. Chen,
D. J. Pouchan, S. Andre´, M. L. Klein, H.-J. Gabius and
V. Percec, J. Am. Chem. Soc., 2015, 137, 13334–13344.
29 Q. Xiao, A.-K. Ludwig, C. Romano`, I. Buzzacchera,
S. E. Sherman, M. Vetro, S. Ve´rtesy, H. Kaltner, E. H. Reed,





























































































View Article OnlineM. L. Klein, H.-J. Gabius and V. Percec, Proc. Natl. Acad. Sci.
U. S. A., 2018, 115, E2509–E2518.
30 S. Andre´, B. Liu, H.-J. Gabius and R. Roy, Org. Biomol. Chem.,
2003, 1, 3909–3916.
31 L. Abbassi, Y. M. Chabre, N. Kottari, A. A. Arnold, S. Andre´,
J. Josserand, H.-J. Gabius and R. Roy, Polym. Chem., 2015,
6, 7666–7683.
32 N. Ahmad, H.-J. Gabius, S. Andre´, H. Kaltner, S. Sabesan,
R. Roy, B. Liu, F. Macaluso and C. F. Brewer, J. Biol. Chem.,
2004, 279, 10841–10847.
33 S. R. Rauthu, T. C. Shiao, S. Andre´, M. C. Miller, E´. Madej,
K. H. Mayo, H.-J. Gabius and R. Roy, ChemBioChem, 2015,
16, 126–139.
34 C. Bonduelle, H. Oliveira, C. Gauche, J. Huang, A. Heise and
S. Lecommandoux, Chem. Commun., 2016, 52, 11251–11254.
35 D. Laaf, P. Bojarova´, H. Pelantova´, V. Krˇen and L. Elling,
Bioconjugate Chem., 2017, 28, 2832–2840.
36 S. Bo¨cker, D. Laaf and L. Elling, Biomolecules, 2015, 5, 1671.
37 G.-J. Boons, Expert Rev. Vaccines, 2010, 9, 1251–1256.
38 V. P. Torchilin, Nat. Rev. Drug Discovery, 2005, 4, 145.
39 B. S. Pattni, V. V. Chupin and V. P. Torchilin, Chem. Rev.,
2015, 115, 10938–10966.
40 R. Stahn, H. Scha¨fer, J. Schreiber and M. Brudel, J. Liposome
Res., 1995, 5, 61–73.
41 C. Sandoval-Altamirano, S. A. Sanchez, N. F. Ferreyra and
G. Gunther, Colloids Surf., B, 2017, 158, 539–546.
42 R. Zeisig, R. Stahn, K. Wenzel, D. Behrens and I. Fichtner,
Biochim. Biophys. Acta, Biomembr., 2004, 1660, 31–40.
43 C. Kelly, C. Jeﬀeries and S.-A. Cryan, J. Drug Delivery, 2011,
2011, 727241.
44 M. Srinivasarao and P. S. Low, Chem. Rev., 2017, 117, 12133–
12164.
45 N. Jayaraman, K. Maiti and K. Naresh, Chem. Soc. Rev., 2013,
42, 4640–4656.
46 J. J. Weingart, P. Vabbilisetty and X. L. Sun, Carbohydrate
Nanotechnology, ed. K. J. Stine, John Wiley & Sons, Inc., 1st
edn, 2016.
47 L. Cai, Z. Gu, J. Zhong, D. Wen, G. Chen, L. He, J. Wu and
Z. Gu, Drug Discovery Today, 2018, 23, 1126–1138.
48 W. C. Chen, G. C. Completo, D. S. Sigal, P. R. Crocker,
A. Saven and J. C. Paulson, Blood, 2010, 115, 4778–4786.
49 N. Kawasaki, J. L. Vela, C. M. Nycholat, C. Rademacher,
A. Khurana, N. van Rooijen, P. R. Crocker, M. Kronenberg
and J. C. Paulson, Proc. Natl. Acad. Sci. U. S. A., 2013, 110,
7826–7831.
50 M. S. Macauley, F. Pfrengle, C. Rademacher, C. M. Nycholat,
A. J. Gale, A. von Drygalski and J. C. Paulson, J. Clin. Invest.,
2013, 123, 3074–3083.
51 J. Zhu, J. Xue, Z. Guo, L. Zhang and R. E. Marchant,
Bioconjugate Chem., 2007, 18, 1366–1369.
52 D. Ponader, F. Wojcik, F. Beceren-Braun, J. Dernedde and
L. Hartmann, Biomacromolecules, 2012, 13, 1845–1852.
53 D. Ponader, P. Maﬀre, J. Aretz, D. Pussak, N. M. Ninnemann,
S. Schmidt, P. H. Seeberger, C. Rademacher, G. U. Nienhaus
and L. Hartmann, J. Am. Chem. Soc., 2014, 136, 2008–2016.
54 C. Gerke, M. F. Ebbesen, D. Jansen, S. Boden, T. Freichel and
L. Hartmann, Biomacromolecules, 2017, 18, 787–796.23496 | RSC Adv., 2019, 9, 23484–2349755 T. Freichel, S. Eierhoﬀ, N. L. Snyder and L. Hartmann, J. Org.
Chem., 2017, 82, 9400–9409.
56 M. Baier, M. Giesler and L. Hartmann, Chem.–Eur. J., 2018,
24, 1619–1630.
57 J. Chen, H.-N. Son, J. J. Hill, S. Srinivasan, F.-Y. Su,
P. S. Stayton, A. J. Convertine and D. M. Ratner,
Nanomedicine, 2016, 12, 2031–2041.
58 S. Boden, K. Wagner, M. Karg and L. Hartmann, Polymers,
2017, 9, 716.
59 M. F. Ebbesen, C. Gerke, P. Hartwig and L. Hartmann, Polym.
Chem., 2016, 7, 7086–7093.
60 K. S. Bu¨cher, H. Yan, R. Creutznacher, K. Ruoﬀ,
A. Mallagaray, A. Grafmu¨ller, J. S. Dirks, T. Kilic,
S. Weickert, A. Rubailo, M. Drescher, S. Schmidt,
G. Hansman, T. Peters, C. Uetrecht and L. Hartmann,
Biomacromolecules, 2018, 19, 3714–3724.
61 G. Zemple´n and E. Pacsu, Ber. Dtsch. Chem. Ges., 1929, 62,
1613–1614.
62 E.-C. Wamhoﬀ, J. Schulze, L. Bellmann, G. Bachem,
F. F. Fuchsberger, J. Rademacher, M. Hermann, B. Del
Frari, R. van Dalen, D. Hartmann, N. van Sorge, O. Seitz,
P. Stoitzner and C. Rademacher, ACS Cent. Sci., 2019, 5,
808–820.
63 P. L. Yeagle, Biochim. Biophys. Acta, Rev. Biomembr., 1985,
822, 267–287.
64 S. Raﬀy and J. Teissie´, Biophys. J., 1999, 76, 2072–2080.
65 J. Senior and G. Gregoriadis, Life Sci., 1982, 30, 2123–2136.
66 Y. Barenholz, J. Controlled Release, 2012, 160, 117–134.
67 M. Danaei, M. Dehghankhold, S. Ataei, F. Hasanzadeh
Davarani, R. Javanmard, A. Dokhani, S. Khorasani and
M. R. Mozafari, Pharmaceutics, 2018, 10, 57.
68 K. N. Clayton, J. W. Salameh, S. T. Wereley and T. L. Kinzer-
Ursem, Biomicrouidics, 2016, 10, 054107.
69 R. I. Jolck, L. N. Feldborg, S. Andersen, S. M. Moghimi and
T. L. Andresen, Adv. Biochem. Eng./Biotechnol., 2011, 125,
251–280.
70 P. Vabbilisetty and X.-L. Sun, Org. Biomol. Chem., 2014, 12,
1237–1244.
71 I. Taniguchi, K. Akiyoshi and J. Sunamoto, Macromol. Chem.
Phys., 1999, 200, 1386–1392.
72 H. Zhang, D. Laaf, L. Elling and R. J. Pieters, Bioconjugate
Chem., 2018, 29, 1266–1275.
73 L. Bumba, D. Laaf, V. Spiwok, L. Elling, V. Krˇen and
P. Bojarova´, Int. J. Mol. Sci., 2018, 19, 372.
74 M. Wolfenden, J. Cousin, P. Nangia-Makker, A. Raz and
M. Cloninger, Molecules, 2015, 20, 7059–7096.
75 P. So¨rme, B. Kahl-Knutsson, U. Wellmar, B.-G. Magnusson,
H. Leﬄer and U. J. Nilsson, in Methods in Enzymology,
Academic Press, 2003, vol. 363, pp. 157–169.
76 T. K. Dam, H.-J. Gabius, S. Andre´, H. Kaltner, M. Lensch and
C. F. Brewer, Biochemistry, 2005, 44, 12564–12571.
77 J. Stegmayr, A. Lepur, B. Kahl-Knutson, M. Aguilar-Moncayo,
A. A. Klyosov, R. A. Field, S. Oredsson, U. J. Nilsson and
H. Leﬄer, J. Biol. Chem., 2016, 291, 13318–13334.
78 K. Saraboji, M. Ha˚kansson, S. Genheden, C. Diehl, J. Qvist,
U. Weininger, U. J. Nilsson, H. Leﬄer, U. Ryde, M. Akke





























































































View Article Online79 I. R. Nabi, J. Shankar and J. W. Dennis, J. Cell Sci., 2015, 128,
2213–2219.
80 M. van Scherpenzeel, E. E. Moret, L. Ballell, R. M. J. Liskamp,
U. J. Nilsson, H. Leﬄer and R. J. Pieters, ChemBioChem, 2009,
10, 1724–1733.
81 M. F. Marchiori, D. E. Pires Souto, L. Oliveira Bortot,
J. Francisco Pereira, L. T. Kubota, R. D. Cummings,
M. Dias-Baruﬃ, I. Carvalho and V. L. Campo, Bioorg. Med.
Chem., 2015, 23, 3414–3425.
82 J. Tejler, H. Leﬄer and U. J. Nilsson, Bioorg. Med. Chem. Lett.,
2005, 15, 2343–2345.
83 V. Denavit, D. Laine´, T. Tremblay, J. St-Gelais and D. Gigue`re,
Trends Glycosci. Glycotechnol., 2018, 30, SE21–SE40.
84 J. M. Fox, M. Zhao, M. J. Fink, K. Kang and G. M. Whitesides,
Annu. Rev. Biophys., 2018, 47, 223–250.
85 C.-e. A. Chang, W. Chen and M. K. Gilson, Proc. Natl. Acad.
Sci. U. S. A., 2007, 104, 1534–1539.This journal is © The Royal Society of Chemistry 201986 A. J. Cagnoni, J. Kovensky and M. L. Uhrig, J. Org. Chem.,
2014, 79, 6456–6467.
87 H. Halimi, A. Rigato, D. Byrne, G. Ferracci, C. Sebban-
Kreuzer, L. El Antak and F. Guerlesquin, PLoS One, 2014, 9,
e111836.
88 M. Sundqvist, A. Welin, J. Elmwall, V. Osla, U. J. Nilsson,
H. Leﬄer, J. Bylund and A. Karlsson, J. Leukocyte Biol.,
2018, 103, 341–353.
89 R.-Y. Yang, P. N. Hill, D. K. Hsu and F.-T. Liu, Biochemistry,
1998, 37, 4086–4092.
90 A. Lepur, E. Salomonsson, U. J. Nilsson and H. Leﬄer, J. Biol.
Chem., 2012, 287, 21751–21756.
91 L. Wu and N. S. Sampson, ACS Chem. Biol., 2014, 9, 468–475.
92 S. Chen, L. Li, C. Zhao and J. Zheng, Polymer, 2010, 51, 5283–
5293.RSC Adv., 2019, 9, 23484–23497 | 23497
